Claims:

1. A non-naturally occurring and/or purified and/or engineered T cell receptor (TCR) having the property of binding to FMNKFIYEI (SEQ ID No: 1) HLA-A2 complex and comprising at least one TCR alpha chain variable domain and at least one TCR beta chain variable domain,

the alpha chain variable domain comprising Q1 to H112 of SEQ ID No: 11, SEQ ID No 12, SEQ ID No 13, SEQ ID No 14 or SEQ ID No 15, and

the beta chain variable domain comprising D1 to T112 of SEQ ID No: 3.

2. The TCR of claim 1 having an alpha chain TRAC constant domain sequence and/or a beta chain TRBC1 or TRBC2 constant domain sequence.

3. The TCR of claim 2, wherein, the alpha and/or beta chain constant domain sequence(s) are modified by truncation or substitution to delete the native disulfide bond between Cys4 of exon 2 of TRAC and Cys2 of exon 2 of TRBC1 or TRBC2.

4. The TCR of claim 2 or claim 3, wherein the alpha and/or beta chain constant domain sequence(s) are modified by substitution of cysteine residues for Thr 48 of TRAC and Ser 57 of TRBC1 or TRBC2, the cysteines forming a disulfide bond between the alpha and beta constant domains of the TCR.

5. The TCR of any preceding claim, which is in single chain format of the type Vα-L-Vβ, Vβ-L-Vα, Vα-Cα-L-Vβ, Vα-L-Vβ-Cβ, or Vα-Cα-L-Vβ-Cβ wherein Vα and Vβ are TCR α and β variable regions respectively, Cα and Cβ are TCR α and β constant regions respectively, and L is a linker sequence.

6. The TCR of any one of claims 1-4, which is an alpha-beta heterodimer.

7. The TCR of any preceding claim associated with a detectable label, a therapeutic agent or a PK modifying moiety.

8. Non-naturally occurring and/or purified and/or engineered nucleic acid encoding the TCR of any one of the preceding claims.

9. A non-naturally occurring and/or purified and/or engineered cell presenting a TCR as claimed in any one of claims 1-7.

10. A cell as claimed in claim 9, which is a T-cell.

11. A cell harbouring

(a) a TCR expression vector which comprises nucleic acid as claimed in claim 8 encoding in a single open reading frame, or two distinct open reading frames, the alpha chain and the beta chain respectively; or

(b) a first expression vector which comprises nucleic acid encoding the alpha chain of a TCR as claimed in any of claims 1 to 7, and a second expression vector which comprises nucleic acid encoding the beta chain of a TCR as claimed in any of claims 1 to 7.

12. A pharmaceutical composition comprising a TCR as claimed in any one of claims 1 to 7 or a cell as claimed in claim 10 or claim 11, together with one or more pharmaceutically acceptable carriers or excipients.

13. A TCR as claimed in any one of claims 1 to 7, or a cell as claimed in claim 9, 10 or 11, for use in medicine.

14. The TCR or the cell of claim 13, for use in the treatment of cancer.

15. The TCR or the cell of claim 14, wherein the treatment comprises adoptive therapy.